© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Prior Authorization Panel Yields Insights Into Role of PBMs in Biosimilar Uptake
Mary Caffrey
March 9 2022
Association of Community Cancer Centers
At a session at the Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the quest for rebates by pharmacy benefit managers (PBMs) prevents uptake on some biosimilars—and could soon bleed over into biosimilar formulary placement.
Biosimilars CEOs: Opportunities Abound, but Regulatory, “Branding” Hurdles Remain
Mary Caffrey
February 24 2022
There remains risk in the US market due to regulatory and legal hurdles—not to mention a combative political environment, according to executives who gathered last week during the “CEOs Unplugged” session at Access! 2022, held by the Association for Accessible Medicines (AAM) in Orlando.
CMS Seeks Answers for Slower-Than-Expected Biosimilar Adoption, Rawal Says
Mary Caffrey
February 21 2022
Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, spoke during the Association for Accessible Medicines' Access! annual meeting, which gathered in Orlando, Florida, February 15-16.
Experts Call for More Regulatory Action to Address Biosimilar Interchangeability Confusion
Skylar Jeremias
February 17 2022
A panel of experts details the current concerns regarding interchangeability designations for biosimilars in the United States and calls for regulators and policy makers to make changes to allow to easier access to biosimilars and greater adoption.
SB12 Eculizumab Biosimilar Candidate Demonstrates PK, PD Equivalence in Phase 1 Trial
Tony Hagen
December 18 2021
American Society of Hematology Annual Meeting and Exposition
In a pharmacokinetic (PK) and pharmacodynamic (PD) trial in healthy participants, Samsung Bioepis' SB12 eculizumab biosimilar candidate demonstrated equivalence to Soliris, the reference product.
Biosimilar-Gedatolisib Combo Elicits Response in Resistant mBC
Tony Hagen
December 14 2021
San Antonio Breast Cancer Symposium
In metastatic breast cancer (mBC) resistant to multiple lines, Herzuma (a trastuzumab biosimilar) plus gedatolisib, an mTOR/PI3K signaling pathway inhibitor, demonstrated value.
